1. A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab 
Fernando S. Velayos, James G. Kahn, William J. Sandborn, Brian G. Feagan 
Clinical Gastroenterology and Hepatology 
Volume 11, Issue 6, Pages (June 2013)
DOI: /j.cgh
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1
Schematic overview of the decision model for managing secondary loss of response. Ab, antibody.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

3. Figure 2
Overview of major decision branches for managing secondary loss of response.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

4. Figure 3
Secondary analyses. Proportion of patients in (A) remission, response, and active disease, and (B) medication dose at week 52. Proportion of time spent in (C) remission, response, and active disease, and (D) dose of medication over 52 weeks. (E) Proportion of patients in remission at the end of each quarter. (F) Proportion of patients in remission at the end of more than 1 quarter.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

5. Figure 4
Base-case probabilistic sensitivity analysis plot of incremental costs ($) vs QALY for testing vs empiric dose-escalation strategy for managing secondary loss of response.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

6. Figure 5
Selected subgroup analyses based on drug antibody, drug concentration, or inflammation. Rates of surgery and proportion of time spent in response, remission, and dose of medication over 52 weeks presented. (A) Anti-drug Ab positive, active inflammation; (B) therapeutic drug concentration, active inflammation; (C) therapeutic drug concentration, minimal/mild inflammation; (D) all groups with active inflammation; (E) all groups with mild/minimal inflammation. Ab, antibody.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions